4.5 Article

The concordance between the volume hotspot and the grade hotspot: a 3-D reconstructive model using the pathology outputs from the PROMIS trial

Journal

PROSTATE CANCER AND PROSTATIC DISEASES
Volume 19, Issue 3, Pages 258-263

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/pcan.2016.7

Keywords

-

Funding

  1. National Institute of Health Research-Health Technology Assessment [09/22/67]
  2. Prostate Cancer UK
  3. UCLH/UCL Biomedical Research Centre
  4. Royal Marsden and Institute for Cancer Research Biomedical Research Centre
  5. University College London (UCL)
  6. MRC [MC_U122861330, G0701302, MC_UU_12023/28, MC_EX_UU_G0800814, G1002509, MC_UU_12023/6, MR/M009092/1, MC_EX_G0800814] Funding Source: UKRI
  7. Medical Research Council [MC_EX_UU_G0800814, G0701302, G1002509, MC_U122861330, MC_EX_G0800814, MR/M009092/1, MC_UU_12023/6, MC_UU_12023/28, MC_UU_12023/20] Funding Source: researchfish
  8. National Institute for Health Research [NF-SI-0514-10059] Funding Source: researchfish

Ask authors/readers for more resources

OBJECTIVES: The rationale for directing targeted biopsy towards the centre of lesions has been questioned in light of prostate cancer grade heterogeneity. In this study, we assess the assumption that the maximum cancer Gleason grade (Gleason grade hotspot) lies within the maximum dimension (volume hotspot) of a prostate cancer lesion. METHODS: 3-D histopathological models were reconstructed using the outputs of the 5-mm transperineal mapping (TPM) biopsies used as the reference test in the pilot phase of Prostate Mri Imaging Study (PROMIS), a paired validating cohort study investigating the performance of multi-parametric magnetic resonance imaging (MRI) against transrectal ultrasound (TRUS) biopsies. The prostate was fully sampled with 5 mm intervals; each core was separately labelled, inked and orientated in space to register 3-D cancer lesions location. The data from the histopathology results were used to create a 3-D interpolated reconstruction of each lesion and identify the spatial coordinates of the largest dimension (volume hot spot) and highest Gleason grade (Gleason grade hotspot) and assess their concordance. RESULTS: Ninety-four men, with median age 62 years (interquartile range, IQR= 58-68) and median PSA 6.5 ng ml(-1) (4.6-8.8), had a median of 80 (169-89) cores each with a median of 4.5 positive cores (0-12). In the primary analysis, the prevalence of homogeneous lesions was 148 (76%; 95% confidence interval (CI) +/- 6.0%). In all, 184 (94 +/- 3.2%) lesions showed concordant hotspots and 11/47 (23 +/- 12.1%) of heterogeneous lesions showed discordant hotspots. The median 3-D distance between discordant hotspots was 12.8 mm (9.9-15.5). These figures remained stable on secondary analyses using alternative reconstructive assumptions. Limitations include a certain degree of error within reconstructed models. CONCLUSIONS: Guiding one biopsy needle to the maximum cancer diameter would lead to correct Gleason grade attribution in 94% of all lesions and 79% of heterogeneous ones if a true hit was obtained. Further correlation of histological lesions, their MRI appearance and the detectability of these hotspots on MRI will be undertaken once PROMIS results are released.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Urology & Nephrology

Prostate cancer in transgender women: what does a urologist need to know?

Mariana Bertoncelli Tanaka, Kirpal Sahota, James Burn, Alison Falconer, Mathias Winkler, Hashim U. Ahmed, Tina G. Rashid

Summary: The risk of prostate cancer in transgender women who have not undergone gender-affirming hormone therapy or surgery is the same as cis males. For transgender women on hormone therapy or after surgery, the incidence of prostate cancer is lower but diagnosis and treatment is more complex. Future research is needed to develop evidence-based guidelines for managing prostate cancer in transgender women.

BJU INTERNATIONAL (2022)

Article Oncology

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial

Richard A. Adams, David J. Fisher, Janet Graham, Jenny F. Seligmann, Matthew Seymour, Richard Kaplan, Emma Yates, Mahesh Parmar, Susan D. Richman, Philip Quirke, Rachel Butler, Ewan Brown, Fiona Collinson, Stephen Falk, Harpreet Wasan, Kai-Keen Shiu, Gary Middleton, Leslie Samuel, Richard H. Wilson, Louise C. Brown, Timothy S. Maughan

Summary: Despite strong evidence of disease control with maintenance therapy, overall survival (OS) remains unaffected. The FOCUS4-N trial demonstrated significant efficacy in progression-free survival (PFS) with maintenance capecitabine therapy, but no significant improvement in OS. Toxicity between the capecitabine and active monitoring groups was comparable, with expected side effects such as fatigue, diarrhea, and hand-foot syndrome.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Review Oncology

Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis

E. J. Bass, A. Pantovic, M. J. Connor, S. Loeb, A. R. Rastinehad, M. Winkler, Rhian Gabe, H. U. Ahmed

Summary: Using MRI-guided biopsy offers superior detection rates of clinically significant PCa and reduces the detection of insignificant PCa compared to TRUS-GB in patients with suspected prostate cancer. However, no individual MRI-GB technique was found to be better in detecting csPCa. Prospective adequately powered randomized controlled trials are needed for further validation.

PROSTATE CANCER AND PROSTATIC DISEASES (2022)

Article Medicine, Research & Experimental

Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer

Louise C. Brown, Janet Graham, David Fisher, Richard Adams, Jenny Seligmann, Matthew Seymour, Richard Kaplan, Emma Yates, Mahesh Parmar, Susan D. Richman, Philip Quirke, Rachel Butler, Kaikeen Shiu, Gary Middleton, Leslie Samuel, Richard H. Wilson, Timothy S. Maughan

Summary: FOCUS4 is a molecularly stratified umbrella trial in metastatic colorectal cancer, using adaptive statistical methodology to close sub-trials and add new therapies. Feedback from investigators at the close of the trial was consolidated into recommendations and lessons learned for similar future trials.

CLINICAL TRIALS (2022)

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

Assessing the clinical performance of artificial intelligence software for prostate cancer detection on MRI COMMENT

Tobias Penzkofer, Anwar R. Padhani, Baris Turkbey, Hashim U. Ahmed

EUROPEAN RADIOLOGY (2022)

Article Medicine, General & Internal

Diagnostic Accuracy of Abbreviated Bi-Parametric MRI (a-bpMRI) for Prostate Cancer Detection and Screening: A Multi-Reader Study

Giorgio Brembilla, Francesco Giganti, Harbir Sidhu, Massimo Imbriaco, Sue Mallett, Armando Stabile, Alex Freeman, Hashim U. Ahmed, Caroline Moore, Mark Emberton, Shonit Punwani

Summary: The study found that abbreviated biparametric MRI protocols can match the diagnostic accuracy of standard biparametric MRI and multiparametric MRI for detecting clinically significant prostate cancer. When used in low-prevalence settings, higher cut-offs for MRI positivity should be prioritized.

DIAGNOSTICS (2022)

Article Oncology

External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer

Bhavna Oza, Tim Eisen, Eleni Frangou, Grant D. Stewart, Axel Bex, Alastair W. S. Ritchie, Rick Kaplan, Benjamin Smith, Ian D. Davis, Martin R. Stockler, Laurence Albiges, Bernard Escudier, James Larkin, Steven Joniau, Barry Hancock, Gregers G. Hermann, Joaquim Bellmunt, Mahesh K. B. Parmar, Patrick Royston, Angela Meade

Summary: This study provides a robust external validation of the 2003 Leibovich score using contemporary data, demonstrating its discriminative accuracy and calibration in predicting risk for patients with locally advanced renal cell carcinoma (RCC). The score can be used to guide risk stratification in adjuvant clinical trials for RCC patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Editorial Material Urology & Nephrology

The unclear role of PET-CT in localized radiorecurrent prostate cancer COMMENT

Alexander Light, Hashim U. Ahmed, Taimur T. Shah

Summary: Recurrence of prostate cancer is common after radical radiotherapy, and accurate detection and localization of the recurrent disease is crucial for treatment planning. While PET-CT is increasingly used to detect metastatic disease, its value for identifying and characterizing intraprostatic recurrence needs improvement.

NATURE REVIEWS UROLOGY (2022)

Article Medicine, General & Internal

Experiences of 'traditional' and 'one-stop' MRI-based prostate cancer diagnostic pathways in England: a qualitative study with patients and GPs

Samuel William David Merriel, Stephanie Archer, Alice S. Forster, David Eldred-Evans, John McGrath, Hashim Uddin Ahmed, Willie Hamilton, Fiona M. Walter

Summary: This study explored patient and GP experiences of prostate cancer diagnostic pathways in England. Patients preferred "one-stop" pathways integrating MRI and specialist consultations, while GPs were uncertain about identifying patients needing urgent prostate cancer testing.

BMJ OPEN (2022)

Letter Urology & Nephrology

Age-related PSA testing for prostate cancer: NICE recommendation 1.6.3

Edward J. J. Bass, Hashim U. U. Ahmed

BJU INTERNATIONAL (2023)

Editorial Material Primary Health Care

Diagnosis of prostate cancer in primary care: navigating updated clinical guidance

Samuel W. D. Merriel, Andrew Seggie, Hashim Ahmed

BRITISH JOURNAL OF GENERAL PRACTICE (2023)

Article Urology & Nephrology

Landmarks in the evolution of prostate biopsy

Martin J. J. Connor, Michael A. A. Gorin, David Eldred-Evans, Edward J. J. Bass, Ankit Desai, Tim Dudderidge, Mathias Winkler, Hashim U. U. Ahmed

Summary: Approaches and techniques for diagnostic prostate biopsy have evolved significantly in recent decades, with advancements from finger-guided techniques to MRI-directed strategies, aspiration cytology to tissue core sampling, and transrectal to transperineal approaches. Transperineal biopsy approaches have particularly improved antibiotic stewardship and reduced infectious complications. Additionally, future prostate biopsy methods may integrate novel techniques such as 3D-ultrasonography fusion reconstruction, molecular targeting based on PET imaging, and autonomous robotic-assisted biopsy. This Perspective reviews the history of prostate biopsy and discusses the current and future role of imaging in prostate biopsy.

NATURE REVIEWS UROLOGY (2023)

Article Oncology

Circulating Chromosome Conformation Signatures Significantly Enhance PSA Positive Predicting Value and Overall Accuracy for Prostate Cancer Detection

Dmitri Pchejetski, Ewan Hunter, Mehrnoush Dezfouli, Matthew Salter, Ryan Powell, Jayne Green, Tarun Naithani, Christina Koutsothanasi, Heba Alshaker, Jiten Jaipuria, Martin J. Connor, David Eldred-Evans, Francesca Fiorentino, Hashim Ahmed, Alexandre Akoulitchev, Mathias Winkler

Summary: Prostate cancer is a common disease affecting one out of six men during their lifetime. The current prostate-specific antigen (PSA) blood test is not accurate, leading to unnecessary biopsies and false reassurance. A new epigenetic test, combined with the PSA test, has been developed and shows better diagnostic accuracy. The new test, called the PSE test, is accurate, rapid, minimally invasive, and inexpensive, and has the potential to significantly improve prostate cancer diagnosis.

CANCERS (2023)

Letter Urology & Nephrology

The 'Leucocyte Coping Capacity' test for identifying radiorecurrent prostate cancer: a pilot study

Alexander Light, Xiaomeng Li, Marjorie Otieno, Hashim U. Ahmed, Taimur T. Shah

BJU INTERNATIONAL (2023)

Article Multidisciplinary Sciences

Mental wellbeing and quality of life in prostate cancer (MIND-P): Protocol for a multi-institutional prospective cohort study

Oliver Brunckhorst, Jaroslaw Liszka, Callum James, Jack B. Fanshawe, Mohamed Hammadeh, Robert Thomas, Shahid Khan, Matin Sheriff, Hashim U. Ahmed, Mieke Van Hemelrijck, Gordon Muir, Robert Stewart, Prokar Dasgupta, Kamran Ahmed

Summary: This study aims to explore the potential treatment, patient, and oncological factors associated with mental wellbeing outcomes in newly diagnosed prostate cancer patients. It will recruit 300 participants undergoing different treatment options for 12-month follow-up and collect questionnaire-based data for analysis. The results will provide clinical value in guiding future prognosis research and identifying individuals in need of additional monitoring or support.

PLOS ONE (2023)

No Data Available